The equipment used in the construction industry is usually associated with a high impact on the environment. Although sustainable design has shown to be a main player among the initiatives focused on reducing environmental impact, it has been driven by the workers and processes, leaving the equipment endeavors in more restrictive and later stages. The equipment industry has been a constant target of environmental standards and economic pressure, but the increasing technological development allows it to respond to sustainability and safety expectations while enhancing its performance. However, there are still several limitations that lead this sector to be one of the last to reach upgrading levels in terms of development. A study identified some gaps in the equipment design that require a greater effort to effectively support the workers and companies towards sustainable construction. This chapter is based on a study aiming to understand the consolidated knowledge of technologically sustainable equipment design and to identify the challenges left for its full development. The findings support the development of innovative eco-friendly equipment, taking into consideration sustainable materials and product guidelines, as well as green economy initiatives. It also supports complex system approaches and safety by design specificities to establish a corporate knowledge of sustainable equipment and align it with the new regulations of the construction industry. The chapter introduces the context of construction equipment in terms of new challenges when faced with the need to provide construction work with a greater capacity for safety, from an environmental and energy efficiency perspective, and within the paradigm of sustainability. Then, it presents the concept of sustainable equipment considering its principles, followed by a characterization of the agents involved in its life cycle.

The pharmaceutical industry is fundamental to global healthcare, providing essential medicines that improve health outcomes and quality of life. However, the demand and supply dynamics within this sector are highly complex, shaped by various factors including demographic changes, evolving disease burdens, technological advancements, regulatory challenges, and economic pressures. This manuscript explores the intricate relationship between pharmaceutical medicine demand and supply, focusing on key strategies that can help companies effectively navigate these challenges. The demand for pharmaceutical products is driven by several factors, such as population growth, the aging population, the rise of chronic diseases, and the emergence of new health threats. Additionally, healthcare accessibility, affordability, and policy changes significantly impact the consumption of medicines, while innovations in medical technologies and therapies create new treatment needs. On the supply side, pharmaceutical companies face challenges related to manufacturing capacity, raw material availability, distribution logistics, and compliance with ever-evolving global regulatory frameworks. To address these challenges, the manuscript discusses strategic approaches to managing both demand and supply in the pharmaceutical sector. Key strategies include advanced demand forecasting through data analytics, optimizing supply chains for efficiency and resilience, implementing just-in-time inventory models, and investing in flexible manufacturing systems. Furthermore, global collaboration and partnerships, as well as effective risk management practices, are highlighted as essential to ensuring the availability of medicines, particularly in times of crisis or global health emergencies. This manuscript also delves into the role of policy advocacy and regulatory harmonization in stabilizing the pharmaceutical market, ensuring that medicines are accessible to all populations. In conclusion, the pharmaceutical industry must continually adapt to meet the evolving challenges of demand and supply, embracing innovation and collaboration while maintaining a focus on patient access and global healthcare equity. Through strategic planning and adaptive solutions, the pharmaceutical sector can ensure the continuous availability of critical medicines worldwide, meeting both current and future health needs.